Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ABBV AbbVie Inc

160,51

-2,04 (-1,25%)

Nach Börsenschluss

Zuletzt aktualisiert: 01:29:35

Verzögert um 15 Minuten

AbbVie announces FDA approval for Skyrizi in psoriatic arthritis

To read the full story on Seeking Alpha, click here.

AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more AbbVie Charts.

AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more AbbVie Charts.

News AbbVie Inc

Form 8-K/A - Current report: [Amend]
Mittwoch 8 Mai 2024 (3 Stunden vor) • Edgar (US Regulatory)

QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
Mittwoch 8 Mai 2024 (12 Stunden vor) • PR Newswire (Canada)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 8 Mai 2024 (24 Stunden vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 8 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 8 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mittwoch 8 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

AbbVie to Present at the Bank of America Securities Healthcare Conference
Montag 6 Mai 2024 (2 Tage vor) • PR Newswire (US)

U.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation Data
Freitag 26 April 2024 (2 Wochen vor) • IH Market News

AbbVie Reports First-Quarter 2024 Financial Results
Freitag 26 April 2024 (2 Wochen vor) • PR Newswire (US)

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Donnerstag 25 April 2024 (2 Wochen vor) • PR Newswire (US)

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Dienstag 23 April 2024 (2 Wochen vor) • PR Newswire (US)

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Donnerstag 18 April 2024 (3 Wochen vor) • PR Newswire (US)

Weitere AbbVie Inc News-Artikel

BNP Paribas (QX)

Energy Select Sector SPDR

Euro vs US Dollar

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen